Bloomington, Ind. — Cook Medical today announced the sale of the remaining Otolaryngology, Head & Neck Surgery (OHNS) product lines, in the latest of a series of strategic decisions aligned to its 5-year vision. Cook signed an agreement with C2Dx, Inc. (a portfolio company of Shore Capital Partners) to purchase the remaining OHNS product portfolio. This agreement does not include employees, facilities or manufacturing equipment.
“As part of a full product review to align with Cook’s strategic vision, we determined that the OHNS product lines would be better served by an organization that wants to grow in that space. We’re excited that C2Dx plans to invest in and grow this portfolio,” said D.J. Sirota, senior vice president of Cook Medical’s MedSurg division. “This opportunity is another example of Cook’s commitment to our strategy, ensuring we have the right focus, and that we are changing to become the company we want to be for patients, customers, and communities.”
Details of the transaction:
- This agreement does not include employees, facilities or manufacturing facilities.
- C2Dx is a privately held medical device company headquartered in Michigan, that acquires and invests in valuable, niche products to propel their impact worldwide.
- Founded in early 2019, C2Dx is led by a team of medical device industry experts who have over a century of combined experience managing growth-oriented teams across the globe.
About Cook Medical
Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we invent, manufacture and deliver a unique portfolio of medical devices to the healthcare systems of the world. Serving patients is a privilege, and we demand the highest standards of quality, ethics and service. We have remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities.